|

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

RECRUITINGSponsored by Palo Alto Veterans Institute for Research
Actively Recruiting
SponsorPalo Alto Veterans Institute for Research
Started2024-08-01
Est. completion2026-08-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07303712

Summary

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age \> or = 18 years
2. HCC confirmed on imaging, BCLC stage 0, A, B, or C
3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

Exclusion Criteria:

1. Not eligible for Y90 procedure
2. Prior surgery or ablation on indicated tumors
3. Patient unable to complete the follow up visits required for clinical care or research -

Conditions4

CancerHepatocellular Carcinoma (HCC)Liver CancerLiver Disease

Locations1 site

VA Palo Alto Health Care System
Palo Alto, California, 94304
Sirish Kishore, MD650-493-5000

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.